TriNetX

Overview

TriNetX is a federated real-world-data network spanning trial design, RWE generation, value-and-access analysis, and drug safety, with depth in provider-sourced EHR data and protocol feasibility. The federated model keeps data ownership at participating provider institutions while letting life-sciences and healthcare customers query a global network of more than 300M patients; The Carlyle Group has been the majority investor since September 2020.

TriNetX is not a claims-based RWE vendor, a CRO, or a hub services operator. The buyer is typically a clinical operations, RWE, HEOR, or market-access team that needs provider-sourced data tied to feasibility and evidence workflows. Validate scope carefully when the manufacturer also needs claims, lab, mortality, or commercial-analytics depth that sits outside the federated provider model.

Platform Capability Model

The framework below standardizes how Rx Almanac evaluates data-technology-platforms capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, TriNetX is evaluated as federated real-world-data network spanning trial design, RWE generation, value-and-access analysis, and drug safety, with depth in provider-sourced EHR data and protocol feasibility.

Capability	Buyer should compare	TriNetX readout
Data aggregation and interoperability	Claims, EHR, CRM, pharmacy, provider, payer, and FHIR/API connectivity with normalization and identity resolution.	Major data foundation. Federated provider-sourced data across a global network without centralizing ownership away from institutions; Zetta Genomics assets added multiomic federation.
Commercial analytics and patient finding	Targeting, segmentation, patient finding, provider analytics, referral leakage, and opportunity sizing.	Adjacent / clinical first. Patient finding works at the protocol-feasibility level; commercial targeting is not the primary use case.
Workflow automation and CRM integration	Case workflows, field workflows, CRM, task automation, document handling, and operational queue management.	Documented strength. Feasibility, protocol design, and evidence workflows are the operating story rather than CRM or sales-force automation.
Provider, payer, and pharmacy network connectivity	Network reach across HCPs, payers, pharmacies, labs, health systems, and transaction endpoints.	Major network reach. The federated provider network across the US, Europe, and the TriNetX Japan K.K. JV is the defining asset; not a pharmacy or payer transaction network.
AI, NLP, and unstructured data extraction	Conversation intelligence, document AI, NLP extraction, predictive models, and model monitoring.	Automation workflow. January 2026 Conversational AI Interface and API extensions let researchers query TriNetX LIVE in natural language; validate guardrails for clinical and regulatory use.
Security, compliance, and governance	HIPAA, SOC2, data-use controls, auditability, consent, privacy, and regulated-workflow safeguards.	Documented strength. Federated model is structurally privacy-preserving; September 2025 Spain ENS high-level certification adds a public governance signal.
Reporting, dashboards, and data delivery	Dashboards, exports, APIs, scheduled reporting, and downstream feeds to analytics or operating teams.	Reporting layer. TriNetX LIVE platform supports query, dashboard, and export workflows; confirm how outputs feed into manufacturer evidence and regulatory packages.

Buyer Fit

• Program fit: Use TriNetX when the operating need is protocol feasibility, provider-sourced RWE, or value-and-access analytics across global institutions without centralizing data ownership.
• Best-fit buyers: Clinical operations, RWE, HEOR, medical-affairs, and market-access teams at pharma and biotech manufacturers; academic medical centers and registries as data partners.
• Less ideal fit: Teams that need claims-only data, commercial CRM, hub services, retail prescription analytics, or a full CRO engagement.
• Commercial fit: Custom / RFP-led; pricing depends on therapeutic-area scope, network coverage, query volume, AI module use, and any regional JV (e.g., Japan) involvement.
• Pre-award diligence: Confirm therapeutic-area coverage in the global network, federated-query governance, refresh cadence, AI guardrails for clinical use, and how outputs flow into evidence and regulatory deliverables.

Differentiators

• Federated data model: Provider institutions retain ownership while a global query layer enables RWE work, which is a structurally different posture than centralized claims aggregators.
• Provider-sourced depth: EHR-grade data covering more than 300M patients includes clinical detail rarely present in claims-only datasets.
• Most-cited RWD source: TriNetX confirmed status as the most-cited RWD source in peer-reviewed research with 2,025+ citations late 2025, with the closest competitor near ~149 citations.
• Genomics federation: April 2026 Zetta Genomics XetaBase asset acquisition extends the federated model into population-scale genomics and multiomic data.
• Regional reach: TriNetX Japan K.K. joint venture with Fujitsu (February 2025) brings anonymized Japanese EHR data into the global network, useful for global RWE strategies.

RFP Questions

• Which therapeutic areas, geographies, and institutions are covered in production, and what gaps would a contract need to fill?
• How does federated query governance work end-to-end across the global network, including consent, data-use rights, and institutional approvals?
• What evidence supports protocol-feasibility and RWE use in similar therapy areas, including peer-reviewed publications and case studies?
• How are Conversational AI and API extensions governed for clinical and regulatory use, including guardrails, audit logs, and validation evidence?
• How do outputs flow into manufacturer evidence packages, regulatory submissions, or HEOR deliverables, and what export rights apply?
• Which Japan JV, European, or other regional capabilities are in scope for a global RWE strategy?
• What is the support model and SLA across TriNetX LIVE, federated queries, and customer success?

Recent Activity

• 2026-04: Acquired key assets of Zetta Genomics (XetaBase) for population-scale genomic capture and analysis, enabling federated multiomic integration.
• 2026-04: Regeneron announced a strategic collaboration and investment in TriNetX.
• 2026-01: Launched Conversational AI Interface and enhanced API capabilities for TriNetX LIVE, allowing natural-language queries across the 300M-patient global network.
• 2025-10: Confirmed status as the most-cited RWD source in peer-reviewed research with 2,025+ citations, far ahead of the closest competitor.
• 2025-09: Achieved Spain ENS (National Security Scheme) high-level certification, signaling rigorous EU data-security standards.
• 2025-02: Launched TriNetX Japan K.K. joint venture with Fujitsu to scale anonymized Japanese patient data into the global federated network.